Reata Pharmaceuticals, Inc. RETA
172.36 +172.36
Day range unavailable
52-week range unavailable
RETA revenue history
Revenue is income from the company’s ordinary business activities.
2,216,000 USD
FY 2022 · Period ended
Coverage: stale. Values in USD; not inflation adjusted.
Reporting currency is USD by the source’s USD conversion factor of 1; the source does not name the currency.
Scroll the table to see all values →
| Fiscal period | Period end | Revenue | YoY change | YoY % |
|---|---|---|---|---|
| FY 2022 | 2022-12-31 | 2,216,000 | -9,274,000 | -80.71% |
| FY 2021 | 2021-12-31 | 11,490,000 | 2,471,000 | 27.40% |
| FY 2020 | 2020-12-31 | 9,019,000 | -17,498,000 | -65.99% |
| FY 2019 | 2019-12-31 | 26,517,000 | -27,072,000 | -50.52% |
| FY 2018 | 2018-12-31 | 53,589,000 | 5,531,000 | 11.51% |
| FY 2017 | 2017-12-31 | 48,058,000 | -1,798,000 | -3.61% |
| FY 2016 | 2016-12-31 | 49,856,000 | -463,000 | -0.92% |
| FY 2015 | 2015-12-31 | 50,319,000 | -1,635,000 | -3.15% |
| FY 2014 | 2014-12-31 | 51,954,000 | Not available | Not available |
Percentage growth is shown only when the same fiscal period one year earlier has a positive value. Missing periods are not estimated.
Company-reported financial statements. Retrieved 2025-01-04T21:03:02.000Z. Retrieval time is not a report date.
Open full statementsUse Add to watchlist above to save this stock.